VascVersa — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VascVersa is a private, pre-clinical stage biotech company pioneering cell therapies for vascular regeneration. Built on extensive academic research from Queen's University Belfast, the company is developing a platform to repair damaged blood vessels, targeting a significant unmet medical need in cardiovascular and ischemic diseases. While currently pre-revenue and with a pipeline in early development, VascVersa is actively engaging with the global cell and gene therapy community, as evidenced by its participation in key industry conferences like ISCT 2024. The company appears to be in a strategic build-out phase, refreshing its public-facing materials while advancing its scientific programs.

Cardiovascular DiseaseVascular DiseasesIschemic Conditions

Technology Platform

Cell therapy platform leveraging progenitor/stem cells for vascular regeneration and repair, utilizing multiomic single-cell analysis for product characterization.

Opportunities

The global burden of vascular diseases like critical limb ischemia and diabetic complications is massive and growing, representing a multi-billion dollar unmet medical need.

Advances in single-cell multiomic analysis provide a powerful tool to develop a more precise and potent cell therapy product, potentially creating a significant competitive advantage.

The regenerative medicine field is attracting substantial investment, increasing opportunities for funding and strategic partnerships.

Risk Factors

The scientific challenge of achieving robust and reproducible vascular regeneration with a cell therapy is significant, with high risk of clinical failure.

As a pre-revenue, private company, VascVersa is dependent on securing large amounts of external capital to advance through expensive clinical development.

The regulatory pathway for cell-based therapies is complex and stringent, requiring extensive manufacturing and control data.

Competitive Landscape

The field of vascular regeneration is competitive, involving large pharma, biotech startups, and academic centers exploring cell therapies (using various cell types), gene therapies, and biomaterial scaffolds. VascVersa's differentiation will hinge on the specific potency, mechanism, and clinical data of its cell product. Success will require demonstrating clear advantages in efficacy, safety, or ease of delivery over other modalities.

More companies in Cell & Gene Therapy →More companies in Ireland →